Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Medical Genetics and Applied Genomics, |
RCV001267968 | SCV001446507 | likely pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Solve- |
RCV004769985 | SCV005091562 | likely pathogenic | Hereditary spastic paraplegia 31 | 2022-06-01 | no assertion criteria provided | provider interpretation | Variant confirmed as disease-causing by referring clinical team |
Prevention |
RCV004731114 | SCV005339677 | likely pathogenic | REEP1-related disorder | 2024-04-05 | no assertion criteria provided | clinical testing | The REEP1 c.32+1G>T variant is predicted to disrupt the GT donor site and interfere with normal splicing. To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Variants that disrupt the consensus splice donor site in REEP1 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |